Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

AVTE

Aerovate Therapeutics (AVTE)

Aerovate Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AVTE
DateTimeSourceHeadlineSymbolCompany
28/03/202400:20GlobeNewswire Inc.Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International ConferenceNASDAQ:AVTEAerovate Therapeutics Inc
26/03/202407:10GlobeNewswire Inc.Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business HighlightsNASDAQ:AVTEAerovate Therapeutics Inc
12/03/202409:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
08/03/202408:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
07/03/202400:00GlobeNewswire Inc.Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board ChairNASDAQ:AVTEAerovate Therapeutics Inc
28/02/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
23/02/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
21/02/202410:38Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
10/02/202408:28Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
25/01/202410:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
18/01/202408:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
09/01/202409:11Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AVTEAerovate Therapeutics Inc
08/01/202423:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTEAerovate Therapeutics Inc
30/12/202310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
28/12/202309:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
23/12/202310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
21/12/202308:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
16/12/202310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
15/12/202308:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
08/12/202310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
30/11/202310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
28/11/202310:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
23/11/202308:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AVTEAerovate Therapeutics Inc
21/11/202308:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTEAerovate Therapeutics Inc
21/11/202308:45GlobeNewswire Inc.Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial HypertensionNASDAQ:AVTEAerovate Therapeutics Inc
14/11/202300:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AVTEAerovate Therapeutics Inc
14/11/202300:00GlobeNewswire Inc.Aerovate Therapeutics Announces Third Quarter Financial Results and Business HighlightsNASDAQ:AVTEAerovate Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AVTE